Eli Lilly to Acquire Psychedelic Developer AtaiBeckley in Deal Worth up to US$3.8 Billion
Eli Lilly, the world’s largest pharmaceutical company by market value, announced on 16 July 2026 that it has agreed to acquire AtaiBeckley, a clinical-stage biotechnology company developing psychedelic-derived drug candidates, in a deal worth up to approximately US$3.8 billion (roughly A$5.8 billion).
The deal
Under the agreement, Lilly will pay US$6.75 per share in cash — an aggregate equity value of about US$2.8 billion — plus a contingent value right of up to US$2.50 per share (about US$1 billion) tied to development and regulatory milestones for the company’s two lead candidates, according to Lilly’s announcement. The transaction is expected to close in the third quarter of 2026.
AtaiBeckley was formed from the combination of atai Life Sciences and the UK-based Beckley Psytech. Its lead candidate, BPL-003 (mebufotenin benzoate), is a synthetic intranasal formulation of the psychedelic compound 5-MeO-DMT, in Phase 3 development for treatment-resistant depression with a Breakthrough Therapy Designation from the US Food and Drug Administration. The company reported that its Phase 2b trial showed reductions in depressive symptoms following a supervised in-clinic session; those results are the company’s own reporting of its trial data. A second candidate, VLS-01, is a DMT-based formulation.
Why it is being watched
Industry coverage has described the acquisition as the largest to date involving a psychedelic drug developer, and a signal that large pharmaceutical companies now see the field as a serious part of the psychiatric drug pipeline. Psychedelic Alpha noted the reaction has been mixed — some observers read it as evidence the field is maturing, while others questioned the terms and what big-pharma ownership means for how these therapies are developed.
What it means for Australians
Nothing changes in Australia as a result of this deal. Mebufotenin (5-MeO-DMT) is not an approved medicine in Australia and is not part of the TGA’s Authorised Prescriber scheme, which applies only to psilocybin for treatment-resistant depression and MDMA for PTSD, prescribed by individually authorised psychiatrists. Any future availability of AtaiBeckley’s candidates in Australia would depend on TGA approval processes that have not begun. The deal matters to Australian readers mainly as an indicator of where global investment in psychedelic medicine is heading — and because decisions by major sponsors often shape which therapies eventually reach Australian regulators.